Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Incyte Joins Rank Of Stocks With 95-Plus Composite Rating

On Wednesday, Incyte got an upgrade for its IBD SmartSelect Composite Rating from 90 to 98.

Looking For The Best Stocks To Buy And Watch? Start Here

The new rating is a sign the stock is outpacing 98% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Incyte is currently forming a consolidation, with an 83.95 buy point. See if the stock can break out in heavy trade at least 40% above average.

One weak spot is the company's 79 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q2, the company posted 0% EPS growth. Top line growth fell to 16%, down from 20% in the prior quarter.

Incyte earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Inhibrx Biosciences and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.